| Krzysztof Moroz, MD | |
|
Tulane Univ.sch. Of Med., (sl79), 1430 Tulane Ave., New Orleans, LA 70112-2699 | |
| (504) 588-5224 | |
| Not Available |
| Full Name | Krzysztof Moroz |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 40 Years |
| Location | Tulane Univ.sch. Of Med., New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548374440 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 77278 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center New Orleans | New orleans, LA | Hospital |
| Tulane Medical Center | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Administrators Of The Tulane Educational Fund | 0446163760 | 369 |
News Archive
Nursing home residents are often cared for by a variety of health care professionals, including licensed nursing staff. Transfers to a hospital can result from multiple factors, such as recurrent falls or medication mismanagement.
In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
› Verified 5 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Nursing home residents are often cared for by a variety of health care professionals, including licensed nursing staff. Transfers to a hospital can result from multiple factors, such as recurrent falls or medication mismanagement.
In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
› Verified 5 days ago
| Entity Name | Administrators Of The Tulane Educational Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528014164 PECOS PAC ID: 0446163760 Enrollment ID: O20031201000636 |
News Archive
Nursing home residents are often cared for by a variety of health care professionals, including licensed nursing staff. Transfers to a hospital can result from multiple factors, such as recurrent falls or medication mismanagement.
In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
› Verified 5 days ago
| Entity Name | Administrators Of The Tulane Educational Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245434224 PECOS PAC ID: 0446163760 Enrollment ID: O20040114000146 |
News Archive
Nursing home residents are often cared for by a variety of health care professionals, including licensed nursing staff. Transfers to a hospital can result from multiple factors, such as recurrent falls or medication mismanagement.
In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
› Verified 5 days ago
| Entity Name | University Medical Center Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083655567 PECOS PAC ID: 7012150311 Enrollment ID: O20130906000137 |
News Archive
Nursing home residents are often cared for by a variety of health care professionals, including licensed nursing staff. Transfers to a hospital can result from multiple factors, such as recurrent falls or medication mismanagement.
In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Krzysztof Moroz, MD Tulane Univ.sch. Of Med., (sl79), 1430 Tulane Ave., New Orleans, LA 70112-2699 Ph: (504) 588-5224 | Krzysztof Moroz, MD Tulane Univ.sch. Of Med., (sl79), 1430 Tulane Ave., New Orleans, LA 70112-2699 Ph: (504) 588-5224 |
News Archive
Nursing home residents are often cared for by a variety of health care professionals, including licensed nursing staff. Transfers to a hospital can result from multiple factors, such as recurrent falls or medication mismanagement.
In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Virologists from the Katholieke Universiteit Leuven in Belgium report that chloroquine, a widely used antimalarial drug, exhibits antiviral activity against the SARS coronavirus. Chloroquine is an inexpensive and safe drug available worldwide.
Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.
› Verified 5 days ago
Dr. Michael Benjamin Defatta, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1901 Perdido St, New Orleans, LA 70112 Phone: 504-568-6031 | |
Dr. Michael Peng-wei Lee, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 3715 Prytania St, New Orleans, LA 70115 Phone: 504-392-4009 | |
Thomas H Carson, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 200 Henry Clay Ave, Children's Hospital- Department Of Pathology, New Orleans, LA 70118 Phone: 504-896-9816 Fax: 504-894-5354 | |
Dr. Gerald Edward Liuzza, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1401 Foucher St, New Orleans, LA 70115 Phone: 504-897-8828 Fax: 504-897-8762 | |
Gregory Neal Sossaman, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-4000 | |
Dr. Terence Thomas Casey, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1401 Foucher St, New Orleans, LA 70115 Phone: 504-897-8418 Fax: 504-897-8762 | |
Samantha Huber, Pathology Medicare: Not Enrolled in Medicare Practice Location: 3001 Earhart Blvd, New Orleans, LA 70125 Phone: 504-658-9660 |